FayeMiriamFellerMD

Hematologic Oncology

Physician

Dr. Feller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2007 - 2010
Icahn School of Medicine at Mount SinaiClass of 2007

PubMed

16 citations
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
John Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, Rami S Komrokji, Steffen Koschmieder, Alessandro M Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman...> ;Future Oncology. 2022 Jul 1
1 citations
Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia.
Alec W Stranahan, Iryna Berezniuk, Sohini Chakraborty, Faye Feller, Mona Khalaj, Christopher Y Park> ;Leukemia. 2022 Jun 1
37 citations
Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation
Camelia Iancu-Rubin, David Gajzer, Goar Mosoyan, Faye M. Feller, John Mascarenhas, Ronald Hoffman> ;Experimental Hematology. 2012 Jul 1

Abstracts/Posters

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapse...
Faye Feller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

GERN Earnings Call for the Period Ending March 31, 2023May 11th, 2023
Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDSJanuary 4th, 2023
Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS PatientsDecember 12th, 2022
Join now to see all